NCT03145298View on ClinicalTrials.gov

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

January 31, 2023

Study Completion Date

March 31, 2023

Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
BIOLOGICAL

Allogeneic Human Cardiosphere-Derived Stem Cells

Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue

BIOLOGICAL

Placebo

For use in Phase 1b - Double-blind randomized control portion of the study

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Cedars-Sinai Medical Center

OTHER

NCT03145298 - ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy | Biotech Hunter | Biotech Hunter